吡格列酮对循环adipocytokine水平的影响,在2型糖尿病患者的胰岛素敏感性。

文章的细节

引用

复制到剪贴板

宫崎骏Y, Mahankali, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA

吡格列酮对循环adipocytokine水平的影响,在2型糖尿病患者的胰岛素敏感性。

中国性金属底座。2004年9月,89 (9):4312 - 9。

PubMed ID

15356026 (在PubMed

]

文摘

我们检查了吡格列酮的影响(PIO)循环adipocytokine水平阐明机制thiazolidinediones改善胰岛素抵抗在2型糖尿病(T2DM)病人体内。23个学科与2型糖尿病(年龄54 + / - 2年,身体质量指数29 + / - 1公斤/米(2))被随机分配接受安慰剂(n = 11)或PIO, 45毫克/天(n = 12), 4个月。治疗前后,受试者收到75 - g口服葡萄糖耐量试验(OGTT);euglycemic胰岛素钳(40亩/ m (2) .min)与3 - (3)H-glucose;测定脂肪量((2)(3)H O);和测量空腹血糖,游离脂肪酸(远期运费协议)、瘦素、脂联素,TNFalpha浓度。PIO 4个月后,空腹血糖浓度(δ= -2.7摩尔/升),意味着OGTT期间血浆葡萄糖(δ= -3.8摩尔/升),和血红蛋白A (1 c)(δ= 1.7%)降低(P < 0.05与安慰剂)没有禁食或post-OGTT血浆胰岛素水平的变化。禁食远期运费协议(δ= 168 micromol /升)和TNFalpha(δ= 0.7 pg / ml)浓度降低(P < 0.05与安慰剂),而脂联素(δ= 8.7 microg /毫升)增加(P < 0.01与安慰剂)。尽管身体脂肪量的增加(δ= 3.4公斤)PIO后,血浆瘦素浓度没有显著变化。没有改变血浆葡萄糖、远期运费协议或adipocytokine安慰剂组受试者中观察到。 During the insulin clamp, endogenous (hepatic) glucose production decreased (Delta = -2.67 micromol/fat-free mass.min, P < 0.05 vs. placebo), whereas metabolic clearance rate of glucose (MCR) increased (Delta = 0.58 ml/fat-free mass.min, P < 0.05 vs. placebo) after PIO. In all subjects, before and after PIO, the decrease in plasma FFA concentration was correlated with the changes in both endogenous (hepatic) glucose production (r = 0.47, P < 0.05) and MCR (r = -0.41, P < 0.05), whereas the increase in plasma adiponectin concentration was correlated with the change in endogenous (hepatic) glucose production (r = -0.70, P < 0.01) and MCR (r = 0.49, P < 0.05). These results suggest that the direct effects of PIO on adipose tissue to decrease plasma FFA levels and increase plasma adiponectin contribute to the improvements in hepatic and peripheral insulin sensitivity and glucose tolerance in patients with T2DM.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
吡格列酮	过氧物酶体proliferator-activated受体γ	蛋白质	人类	是的	受体激动剂	细节